ZIOPHARM Oncology (NASDAQ:ZIOP) PT Set at $5.50 by Raymond James
Raymond James set a $5.50 target price on ZIOPHARM Oncology (NASDAQ:ZIOP) in a research note published on Friday morning, BayStreet.CA reports. The brokerage currently has an outperform rating on the biotechnology company’s stock.
ZIOP has been the subject of a number of other reports. Jefferies Financial Group started coverage on ZIOPHARM Oncology in a research note on Friday, June 19th. They set a buy rating and a $7.00 price target for the company. ValuEngine raised ZIOPHARM Oncology from a hold rating to a buy rating in a research note on Friday, May 1st. HC Wainwright reissued a buy rating and set a $5.50 price target (down from $6.50) on shares of ZIOPHARM Oncology in a research note on Monday, May 11th. Laidlaw reissued a buy rating and set a $7.50 price target on shares of ZIOPHARM Oncology in a research note on Sunday, June 21st. Finally, Cantor Fitzgerald reissued a market perform rating and set a $6.00 price target on shares of ZIOPHARM Oncology in a research note on Sunday, June 21st. Three analysts have rated the stock with a hold rating and five have given a buy rating to the company. The stock has a consensus rating of Buy and an average price target of $5.75.
NASDAQ ZIOP opened at $3.26 on Friday. The firm has a market cap of $722.16 million, a price-to-earnings ratio of -4.66 and a beta of 2.58. The company has a quick ratio of 11.56, a current ratio of 11.56 and a debt-to-equity ratio of 0.01. The business has a 50-day moving average price of $3.23 and a 200-day moving average price of $3.30. ZIOPHARM Oncology has a twelve month low of $1.79 and a twelve month high of $7.25.
Several large investors have recently bought and sold shares of the company. State Street Corp lifted its stake in shares of ZIOPHARM Oncology by 7.8% in the 1st quarter. State Street Corp now owns 6,398,385 shares of the biotechnology company’s stock valued at $15,676,000 after purchasing an additional 460,794 shares during the last quarter. Royal Bank of Canada lifted its stake in shares of ZIOPHARM Oncology by 83.9% in the 1st quarter. Royal Bank of Canada now owns 13,927 shares of the biotechnology company’s stock valued at $34,000 after purchasing an additional 6,353 shares during the last quarter. Public Employees Retirement Association of Colorado raised its holdings in shares of ZIOPHARM Oncology by 41.9% in the first quarter. Public Employees Retirement Association of Colorado now owns 39,565 shares of the biotechnology company’s stock worth $97,000 after buying an additional 11,680 shares during the period. Morgan Stanley raised its holdings in shares of ZIOPHARM Oncology by 13.5% in the first quarter. Morgan Stanley now owns 1,339,584 shares of the biotechnology company’s stock worth $3,282,000 after buying an additional 158,882 shares during the period. Finally, Voloridge Investment Management LLC purchased a new stake in shares of ZIOPHARM Oncology in the first quarter worth approximately $194,000. 46.13% of the stock is owned by institutional investors and hedge funds.
ZIOPHARM Oncology Company Profile
ZIOPHARM Oncology, Inc, a biotechnology company, focuses on acquiring, developing, and commercializing a portfolio of immuno-oncology therapies for treating heterogenous solid tumors and unknown antigens. The company develops two immuno-oncology platform technologies, including Sleeping Beauty (SB), which is based on the genetic engineering of immune cells using a non-viral transposon/transposase system to reprogram T-cells outside of the body for infusion; and Controlled IL-12, which delivers interleukin 12 or IL-12, a master regular of the immune system, in a controlled and safe manner to focus the patient's immune system to attack cancer cells.
Featured Story: Average Daily Trade Volume – What You Need to Know
Receive News & Ratings for ZIOPHARM Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ZIOPHARM Oncology and related companies with MarketBeat.com's FREE daily email newsletter.